PhRMA

11/17/2025

A single case of measles can cost up to $60,000 in medical care. When outbreaks spread, those costs can quickly multiply into millions.

But the true cost goes beyond dollars. Every preventable case puts vulnerable people—infants, those with weakened immune systems, and entire communities—at risk.

The measles vaccine is safe and 97% effective at preventing infection. By keeping vaccination rates strong, we can protect one another, prevent avoidable suffering, and reduce the strain on our health-care system.

https://phrma.org/blog/new-study-measles-setbacks-harm-health-and-america-s-economy

11/14/2025

The biopharma industry is doing their part to lower medicine costs by launching direct purchase programs to increase access for patients and deliver transparent pricing, and investing in jobs, the economy and cures here at home. But we can’t do it alone. Washington must end the middlemen markups by PBMs and 340B hospitals.

11/11/2025

Biogen’s investment in North Carolina’s Research Triangle Park is a testament to our industry’s commitment to U.S. manufacturing, skilled job creation and patient-centered innovation. By fostering a hub for biotech innovation, Biogen is advancing their commitment to deliver transformative treatments and foster growth among the local veterans, patients and leaders that make up its workforce.

Learn more: https://innovation.org/casestudy/biogen-deepens-u-s-manufacturing-footprint/

11/10/2025

While biopharmaceutical companies are delivering transparent pricing through direct purchase programs and investing in cures here at home, middlemen continue to drive up drug costs for Americans.

The fact is America is the only country where half of every dollar spent on brand medicines go to entities that don’t make them.

As policymakers continue to look for ways to address rising health care costs and spending on medicines, they must address where half the dollar is going.

End middlemen markups. Put American patients first.
https://phrma.org/policy-issues/patient-access-affordability

11/08/2025

Happy National STEM Day! Today, not only are we honoring the dedicated individuals shaping the future of medicine and health, but we are celebrating our industry’s major investments in STEM jobs and programs across the country.

Together, we’re building the world’s greatest STEM workforce and developing the next wave of cutting-edge medicines.

Read more:
https://phrma.org/blog/celebrating-stem-day-investing-in-america-s-innovators

11/06/2025

Last month, as part of a major announcement on industry investments in America, biopharmaceutical companies made a historic $500 billion commitment to strengthen U.S. manufacturing and R&D.

Now, that investment is already taking shape — companies like AstraZeneca, Lilly, Astellas, Bristol Myers Squibb, and Amgen are expanding cutting-edge facilities across the country.

These projects are creating jobs, fueling innovation, and ensuring lifesaving medicines are discovered and made right here in America.

🔗 See how PhRMA members are turning commitment into action →

11/05/2025

After investing more than $12.5 billion to expand manufacturing in Virginia, Eli Lilly, AstraZeneca and Merck are committing an additional $120 million to launch a new manufacturing training center.

This is what the industry’s $500 billion commitment to U.S. manufacturing looks like in action. We’re building capacity, strengthening supply chains, and investing in people.

Learn more:

AstraZeneca, Eli Lilly & Merck pledge $40M each for Virginia manufacturing training center after investing $12.5B in state facilities. Will train 2000+ yearly.

11/05/2025

The 340B hospital markup program costs an estimated $20 billion each year in lost Medicare and Medicaid rebates.

That’s a hidden tax on patients, taxpayers, and employers.

Without greater transparency and oversight, this number will only continue to grow. At the same time, there’s no evidence that patients are benefitting from the program. It’s time to fix 340B.

https://phrma.org/blog/340b-abuses-are-fueling-higher-medicare-costs-new-brg-report-shows

11/03/2025

The Senate HELP Committee hearing highlighted how the 340B hospital markup program is driving up costs for patients, taxpayers and employers.

According to the nonpartisan CBO, 340B is costing taxpayers billions and they found no evidence of patient benefit.

It’s time to fix 340B.

https://www.thewellnews.com/bipartisan/bipartisan-senate-lawmakers-scrutinize-340b-program-call-for-reforms/

11/03/2025

Hepatitis B is up to 100x more contagious than HIV—and newborns are especially vulnerable.

The vaccine given shortly after birth has cut infections in kids by 99%. Vaccine innovation and access save lives.

Learn why it matters.
https://phrma.org/blog/why-the-hepatitis-b-vaccine-matters

11/01/2025

The Research Triangle Park region shows what happens when federal and state policies support bold investment in biopharmaceutical manufacturing.

Here, investment has fueled not only the discovery of new cures but also strong economic growth, good-paying jobs, and broad multiplier effects across local communities.

This region is proof that when the right policies are in place, innovation and opportunity thrive—and a reminder of why these policies must be protected.

https://innovation.org/american-investment/

10/31/2025

Hospitals are using scare tactics in an attempt to block the Health Resources and Services Administration’s (HRSA) commonsense 340B rebate model pilot.

Lawmakers and the administration shouldn’t fall for it—and should support the rebate model pilot, an important step to help restore transparency, enforce basic rules, and ensure the 340B program works for patients.

https://phrma.org/blog/340b-hospitals-use-scare-tactics-to-evade-accountability